Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • Perspective Therapeutics' Capital Expenditures fell 9329.59% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year decrease of 4412.49%. This contributed to the annual value of $54.4 million for FY2024, which is 497593.28% up from last year.
  • Per Perspective Therapeutics' latest filing, its Capital Expenditures stood at $2.0 million for Q3 2025, which was down 9329.59% from $1.0 million recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Capital Expenditures high stood at $29.7 million for Q3 2024, and its period low was -$86000.0 during Q4 2021.
  • Over the past 5 years, Perspective Therapeutics' median Capital Expenditures value was $214000.0 (recorded in 2023), while the average stood at $3.5 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 24333.33% in 2021, then skyrocketed by 1632022.47% in 2024.
  • Over the past 5 years, Perspective Therapeutics' Capital Expenditures (Quarter) stood at -$86000.0 in 2021, then surged by 275.58% to $151000.0 in 2022, then tumbled by 41.06% to $89000.0 in 2023, then soared by 16320.22% to $14.6 million in 2024, then crashed by 86.37% to $2.0 million in 2025.
  • Its Capital Expenditures was $2.0 million in Q3 2025, compared to $1.0 million in Q2 2025 and $4.7 million in Q1 2025.